New Drug Products of 2010

  • Bepreve

    Bepreve

    Indication(s): Treatment of itching due to allergic conjunctivitis.

  • Saphris

    Saphris

    Indication(s): For the acute treatment of: 1) schizophrenia; 2) manic or mixed episodes associated with bipolar I disorder.

  • Zenpep

    Zenpep

    Indication(s): Exocrine pancreatic insufficiency (eg, cystic fibrosis).

  • Vibativ

    Vibativ

    Indication(s): Complicated skin and skin structure infections due to susceptible gram (+) bacteria.

  • Actemra

    Actemra

    Indication(s): Moderately-to severely-active rheumatoid arthritis in patients who have had an inadequate response to ≥1 TNF blocker. May be used with methotrexate or DMARDs.

  • Fanapt

    Fanapt

    Indication(s): Acute treatment of schizophrenia.

  • Victoza

    Victoza

    Indication(s): As adjunct to diet and exercise, to improve glycemic control in type 2 diabetes.

  • Ampyra

    Ampyra

    Indication(s): To improve walking in patients with multiple sclerosis (demonstrated by an increase in walking speed).

  • Menveo

    Menveo

    Indication(s): Meningitis immunization.

  • Silenor

    Silenor

    Indication(s): Treatment of insomnia characterized by difficulty with sleep maintenance.

  • Cayston

    Cayston

    Indication(s): To improve respiratory symptoms in cystic fibrosis (CF) patients with <i>Pseudomonas aeruginosa.</i>

  • Iprivask

    Iprivask

    Indication(s): DVT prophylaxis in patients undergoing hip replacement surgery.

  • Zyclara

    Zyclara

    Indication(s): Actinic keratoses on face and balding scalp in immunocompetent patients.

  • Qutenza

    Qutenza

    Indication(s): Management of neuropathic pain associated with post-herpetic neuralgia.

  • Exalgo

    Exalgo

    Indication(s): Moderate to severe pain when continuous opioid analgesia is needed for an extended time period. Not for as-needed use or to treat acute or post-op pain. For use in opioid-tolerant patients only.

  • Xifaxan 550mg

    Xifaxan 550mg

    Indication(s): Reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥18 years of age.

  • Lysteda

    Lysteda

    Indication(s): Cyclic heavy menstrual bleeding.

  • Natazia

    Natazia

    Indication(s): Oral contraception.

  • Prolia

    Prolia

    Indication(s): In postmenopausal women with osteoporosis: at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other therapy; to reduce incidence of vertebral, nonvertebral, and hip fractures.

  • Rybix ODT

    Rybix ODT

    Indication(s): Moderate to moderately severe pain in adults.

  • Livalo

    Livalo

    Indication(s): Adjunct to diet: To reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.

  • Dulera

    Dulera

    Indication(s): Maintenance treatment of asthma in patients not adequately controlled on other asthma-controller medications or whose disease severity warrants initiation of both an inhaled steroid and a long acting β2-agonist.

  • Vimovo

    Vimovo

    Indication(s): Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis: to improve symptoms and reduce risk of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

  • Tribenzor

    Tribenzor

    Indication(s): Hypertension. Not for initial therapy.

  • Jalyn

    Jalyn

    Indication(s): Benign prostatic hyperplasia (BPH).

  • Oravig

    Oravig

    Indication(s): Local treatment of oropharyngeal candidiasis.

  • Tekamlo

    Tekamlo

    Indication(s): Hypertension.

  • Gilenya

    Gilenya

    Indication(s): For relapsing forms of multiple sclerosis (MS): to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

  • Beyaz

    Beyaz

    Indication(s): Oral contraception. Premenstrual dysphoric disorder (PMDD) in women who choose an oral contraceptive for contraception. Moderate acne vulgaris in women ≥14 years old who choose an oral contraceptive for contraception. To raise folate levels in women who choose to use an oral contraceptive for contraception.

  • Pradaxa

    Pradaxa

    Indication(s): To reduce risk of stroke and systemic embolism in non-valvular atrial fibrillation.

  • Krystexxa

    Krystexxa

    Indication(s): Chronic gout in adult patients refractory to conventional therapy.

Next Prev

A sampling of the new drug products featured on eMPR.com in 2010. For a recapitulation of all the new drug products in 2010 click here.